Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00591136 | Phase I Study of Indibulin in Patients With Solid Tumors | PHASE1 | COMPLETED | 47 | — | — | Apr 1, 2003 | Sep 1, 2008 | Jul 19, 2012 | 2 | Netherlands |
| Arm | Type | Description |
|---|---|---|
| Single Arm | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| indibulin | DRUG | Dose escalation, daily dosing for 14 days every 3 weeks, for up to 4 months |
Inclusion Criteria * Male or female patient, \>= 18 years of age. * Histologically/cytologically proven solid malignant tumor, for which standard treatment of proven efficacy are not or no longer available. * Performance status 0-2 ECOG/WHO. * Life expectancy \> 3 months. * Able and willing to unde...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |